Theiler's murine encephalomyelitis virus as a vaccine candidate for immunotherapy

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Pavelko, Kevin D ^a   Girtman, Megan A ^a   Mitsunaga, Yoshihiro ^a,c   Mendez Fernandez, Yanice V ^a,d   Bell, Michael P ^a   Hansen, Michael J ^a   Allen, Kathleen S ^a   Rodriguez, Moses ^a,b   Pease, Larry R ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c Tagawa shinsei Hospital   (Japan)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MURINE ENCEPHALOMYELITIS VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; PRIMER DNA;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNIZATION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DIABETES MELLITUS; LYMPHOCYTIC INFILTRATION; MELANOMA; MOUSE; MURINE ENCEPHALOMYELITIS VIRUS; NONHUMAN; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; VACCINE PRODUCTION; VIRUS GENOME; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY;

ANIMALIA; PICORNAVIRIDAE; THEILER'S ENCEPHALOMYELITIS VIRUS;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; DNA PRIMERS; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY, AMINO ACID; THEILOVIRUS; VIRAL VACCINES;

EID: 79956300385     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020217     Document Type: Article

References (41)

1. Borrow P, Tonks P, Welsh CJ, Nash AA, (1992) The role of CD8+T cells in the acute and chronic phases of Theiler's murine encephalomyelitis virus-induced disease in mice. J Gen Virol 73 (Pt 7): 1861-1865.
2. Rodriguez M, Leibowitz J, David CS, (1986) Susceptibility to Theiler's virus-induced demyelination. Mapping of the gene within the H-2D region. J Exp Med 163: 620-631.
3. Borson ND, Paul C, Lin X, Nevala WK, Strausbauch MA, et al. (1997) Brain-infiltrating cytolytic T lymphocytes specific for Theiler's virus recognize H2Db molecules complexed with a viral VP2 peptide lacking a consensus anchor residue. J Virol 71: 5244-5250.
4. Dethlefs S, Escriou N, Brahic M, van der Werf S, Larsson-Sciard EL, (1997) Theiler's virus and Mengo virus induce cross-reactive cytotoxic T lymphocytes restricted to the same immunodominant VP2 epitope in C57BL/6 mice. J Virol 71: 5361-5365.
5. Johnson AJ, Njenga MK, Hansen MJ, Kuhns ST, Chen L, et al. (1999) Prevalent class I-restricted T-cell response to the Theiler's virus epitope Db:VP2121-130 in the absence of endogenous CD4 help, tumor necrosis factor alpha, gamma interferon, perforin, or costimulation through CD28. J Virol 73: 3702-3708.
6. Kang MH, So EY, Park H, Kim BS, (2008) Replication of Theiler's virus requires NF-kappa B-activation: higher viral replication and spreading in astrocytes from susceptible mice. Glia 56: 942-953.
7. Olson JK, Eagar TN, Miller SD, (2002) Functional activation of myelin-specific T cells by virus-induced molecular mimicry. J Immunol 169: 2719-2726.
8. Amato RJ, (2010) 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy. Expert Opin Biol Ther 10: 281-287.
9. Gallo P, Dharmapuri S, Cipriani B, Monaci P, (2005) Adenovirus as vehicle for anticancer genetic immunotherapy. Gene Ther 12 (Suppl 1): S84-91.
10. Dunlop LR, Oehlberg KA, Reid JJ, Avci D, Rosengard AM, (2003) Variola virus immune evasion proteins. Microbes Infect 5: 1049-1056.
11. Schagen FH, Ossevoort M, Toes RE, Hoeben RC, (2004) Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion. Crit Rev Oncol Hematol 50: 51-70.
12. Hemmi S, Geliebter J, Zeff RA, Melvold RW, Nathenson SG, (1988) Three spontaneous H-2Db mutants are generated by genetic micro-recombination (gene conversion) events. Impact on the H-2-restricted immune responsiveness. J Exp Med 168: 2319-2335.
13. Roos RP, Stein S, Ohara Y, Fu JL, Semler BL, (1989) Infectious cDNA clones of the DA strain of Theiler's murine encephalomyelitis virus. J Virol 63: 5492-5496.
14. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR, (1989) Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77: 51-59.
15. Rodriguez M, Leibowitz JL, Lampert PW, (1983) Persistent infection of oligodendrocytes in Theiler's virus-induced encephalomyelitis. Ann Neurol 13: 426-433.
16. Rodriguez M, Leibowitz JL, Powell HC, Lampert PW, (1983) Neonatal infection with the Daniels strain of Theiler's murine encephalomyelitis virus. Lab Invest 49: 672-679.
17. Parish CR, Glidden MH, Quah BJ, Warren HS, (2009) Use of the intracellular fluorescent dye CFSE to monitor lymphocyte migration and proliferation. Curr Protoc Immunol Chapter 4: Unit4 9.
18. Block MS, Mendez-Fernandez YV, Van Keulen VP, Hansen MJ, Allen KS, et al. (2005) Inability of bm14 mice to respond to Theiler's murine encephalomyelitis virus is caused by defective antigen presentation, not repertoire selection. J Immunol 174: 2756-2762.
19. Lipton HL, Kim BS, Yahikozawa H, Nadler CF, (2001) Serological evidence that Mus musculus is the natural host of Theiler's murine encephalomyelitis virus. Virus Res 76: 79-86.
20. Zoll J, Erkens Hulshof S, Lanke K, Verduyn Lunel F, Melchers WJ, et al. (2009) Saffold virus, a human Theiler's-like cardiovirus, is ubiquitous and causes infection early in life. PLoS Pathog 5: e1000416.
21. Reddi HV, Kallio P, Lipton HL, (2003) Galactose is needed only for expression of co-receptors used by Theiler's murine encephalomyelitis virus as the virus does not directly bind galactose or use the UDP-galactose transporter as a receptor. J Gen Virol 84: 845-849.
22. Hwang C, Sanda MG, (1999) Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy. Curr Opin Mol Ther 1: 471-479.
23. Myoung J, Hou W, Kang B, Lyman MA, Kang JA, et al. (2007) The immunodominant CD8+ T cell epitope region of Theiler's virus in resistant C57BL/6 mice is critical for anti-viral immune responses, viral persistence, and binding to the host cells. Virology 360: 159-171.
24. Nitayaphan S, Toth MM, Roos RP, (1985) Localization of a neutralization site of Theiler's murine encephalomyelitis viruses. J Virol 56: 887-895.
25. Reiman JM, Kmieciak M, Manjili MH, Knutson KL, (2007) Tumor immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol 17: 275-287.
26. Jnaoui K, Minet M, Michiels T, (2002) Mutations that affect the tropism of DA and GDVII strains of Theiler's virus in vitro influence sialic acid binding and pathogenicity. J Virol 76: 8138-8147.
27. Kumar AS, Kallio P, Luo M, Lipton HL, (2003) Amino acid substitutions in VP2 residues contacting sialic acid in low-neurovirulence BeAn virus dramatically reduce viral binding and spread of infection. J Virol 77: 2709-2716.
28. Lin X, Sato S, Patick AK, Pease LR, Roos RP, et al. (1998) Molecular characterization of a nondemyelinating variant of Daniel's strain of Theiler's virus isolated from a persistently infected glioma cell line. J Virol 72: 1262-1269.
29. Calenoff MA, Badshah CS, Dal Canto MC, Lipton HL, Rundell MK, (1995) The leader polypeptide of Theiler's virus is essential for neurovirulence but not for virus growth in BHK cells. J Virol 69: 5544-5549.
30. Badshah C, Calenoff MA, Rundell K, (2000) The leader polypeptide of Theiler's murine encephalomyelitis virus is required for the assembly of virions in mouse L cells. J Virol 74: 875-882.
31. van Pesch V, van Eyll O, Michiels T, (2001) The leader protein of Theiler's virus inhibits immediate-early alpha/beta interferon production. J Virol 75: 7811-7817.
32. Delhaye S, van Pesch V, Michiels T, (2004) The leader protein of Theiler's virus interferes with nucleocytoplasmic trafficking of cellular proteins. J Virol 78: 4357-4362.
33. Lukashev AN, (2010) Recombination among picornaviruses. Rev Med Virol 20: 327-337.
34. Jones MS, Lukashov VV, Ganac RD, Schnurr DP, (2007) Discovery of a novel human picornavirus in a stool sample from a pediatric patient presenting with fever of unknown origin. J Clin Microbiol 45: 2144-2150.
35. Zhang G, Haydon DT, Knowles NJ, McCauley JW, (1999) Molecular evolution of swine vesicular disease virus. J Gen Virol 80 (Pt 3): 639-651.
36. Lindsley MD, Thiemann R, Rodriguez M, (1991) Cytotoxic T cells isolated from the central nervous systems of mice infected with Theiler's virus. J Virol 65: 6612-6620.
37. Rossi CP, McAllister A, Tanguy M, Kagi D, Brahic M, (1998) Theiler's virus infection of perforin-deficient mice. J Virol 72: 4515-4519.
38. Budhu S, Loike JD, Pandolfi A, Han S, Catalano G, et al. (2010) CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues. J Exp Med 207: 223-235.
39. Au GG, Lincz LF, Enno A, Shafren DR, (2007) Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. Br J Haematol 137: 133-141.
40. Goetz C, Gromeier M, (2010) Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme. Cytokine Growth Factor Rev 21: 197-203.
41. Hales LM, Knowles NJ, Reddy PS, Xu L, Hay C, et al. (2008) Complete genome sequence analysis of Seneca Valley virus-001, a novel oncolytic picornavirus. J Gen Virol 89: 1265-1275.